Peptide pipeline tracker
Every peptide with an international nonproprietary name that has reached phase 2 or beyond in ChEMBL, 331 molecules, with what ClinicalTrials.gov says about their active studies. Read on October 1, 2026; 97 have an active study and 78 have an entry in the encyclopedia.
Dates here are registered primary completion dates: when a sponsor expects a trial's main data collection to end. They are estimates the sponsor can move, not results and not approval decisions, and no FDA decision date (PDUFA) is listed because none is in the data. Download: pipeline-data.json.
Expected in the next 90 days
Readouts registered for October 1, 2026 to December 30, 2026, earliest first; a date given only as a month counts if the month overlaps the window. 33 in all.
- amlintide: trial expected to reach primary completion October 2026 (NCT07506369, recruiting). Pancreatic Polypeptide as a Modulator of Amylin- Induced Satiety in Healthy Humans
- dulaglutide: Phase 3 trial expected to reach primary completion October 1, 2026 (NCT06257966, active not recruiting). A Phase 3 Study to Evaluate the Efficacy of JY09 Compared With Dulaglutide in Combination Therapy Diabetes Mellitus Type 2 Patients With Metformin
- linaclotide: Phase 4 trial expected to reach primary completion October 2026 (NCT03119584, active not recruiting). Efficacy of Linaclotide in Type II Diabetics With Chronic Constipation
- oxytocin: Phase 2 trial expected to reach primary completion October 2026 (NCT06036004, recruiting). Oxytocin Substitution Therapy in Patients With Central Diabetes Insipidus
- pancreatic polypeptide: trial expected to reach primary completion October 2026 (NCT07506369, recruiting). Pancreatic Polypeptide as a Modulator of Amylin- Induced Satiety in Healthy Humans
- pramlintide: trial expected to reach primary completion October 2026 (NCT07506369, recruiting). Pancreatic Polypeptide as a Modulator of Amylin- Induced Satiety in Healthy Humans
- retatrutide: Phase 3 trial expected to reach primary completion October 2026 (NCT06297603, active not recruiting). Effect of Retatrutide Compared With Placebo in Participants With Type 2 Diabetes and Moderate or Severe Renal Impairment, With Inadequate Glycemic Control on Basal Insulin, With or Without Metformin and/or SGLT2 Inhibitor (TRANSCEND-T2D-3)
- vasopressin: Phase 4 trial expected to reach primary completion October 1, 2026 (NCT02118467, recruiting). Vasoactive Drugs in Intensive Care Unit
- semaglutide: Phase 2 trial expected to reach primary completion October 15, 2026 (NCT07505303, active not recruiting). MIST (Metabolic Intervention With Semaglutide and THR-β Therapy) Trial
- vipivotide tetraxetan: Phase 2 trial expected to reach primary completion October 15, 2026 (NCT06894511, active not recruiting). An Open-label Study of Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI Versus AAA617 in PSMA Positive First-line mCRPC
- pasireotide: Phase 2 trial expected to reach primary completion October 29, 2026 (NCT05928390, active not recruiting). Pasireotide s.c. in Patients With Post-Bariatric Hypoglycaemia
- pasireotide diaspartate: Phase 2 trial expected to reach primary completion October 29, 2026 (NCT05928390, active not recruiting). Pasireotide s.c. in Patients With Post-Bariatric Hypoglycaemia
- tirzepatide: Phase 4 trial expected to reach primary completion October 30, 2026 (NCT06861439, active not recruiting). GLP-1s to Enhance Lasting Optimal Weight
- ganirelix: Phase 4 trial expected to reach primary completion October 31, 2026 (NCT06745466, recruiting). Disentangling the Effects of Daily Stress, Sleep, and Sex Hormones on Accelerated Vascular Aging in Midlife Women
- setmelanotide: Phase 2 trial expected to reach primary completion October 31, 2026 (NCT06772597, active not recruiting). A Study of Setmelanotide in Patients With Prader-Willi Syndrome
- bulevirtide: Phase 2 trial expected to reach primary completion November 2026 (NCT07142811, active not recruiting). A Study to Evaluate Tobevibart+Elebsiran Versus Bulevirtide in Chronic HDV Infection
- degarelix: Phase 2 trial expected to reach primary completion November 2026 (NCT03951831, active not recruiting). REGN2810 Followed by Chemoimmunotherapy for Newly Metastatic Hormone-sensitive Prostate Cancer
- goserelin: Phase 2 trial expected to reach primary completion November 2026 (NCT05607004, active not recruiting). (Z)-Endoxifen for the Treatment of Premenopausal Women With ER+/HER2- Breast Cancer
- lanreotide: Phase 3 trial expected to reach primary completion November 2026 (NCT05050942, active not recruiting). A Trial to Assess Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With GEP-NET
- octreotide: Phase 3 trial expected to reach primary completion November 2026 (NCT05050942, active not recruiting). A Trial to Assess Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With GEP-NET
- gallium oxodotreotide: Phase 2 trial expected to reach primary completion November 2, 2026 (NCT05691465, recruiting). Testing the Safety and Effectiveness of Radiation-based Treatment (Lutetium Lu 177 Dotatate) for Metastatic Prostate Cancer That Has Neuroendocrine Cells
- lutetium oxodotreotide: Phase 2 trial expected to reach primary completion November 2, 2026 (NCT05691465, recruiting). Testing the Safety and Effectiveness of Radiation-based Treatment (Lutetium Lu 177 Dotatate) for Metastatic Prostate Cancer That Has Neuroendocrine Cells
- lutetium oxodotreotide lu-177: Phase 2 trial expected to reach primary completion November 2, 2026 (NCT05691465, recruiting). Testing the Safety and Effectiveness of Radiation-based Treatment (Lutetium Lu 177 Dotatate) for Metastatic Prostate Cancer That Has Neuroendocrine Cells
- buserelin: Phase 3 trial expected to reach primary completion November 11, 2026 (NCT05050084, active not recruiting). Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score, The Guidance Trial
- histrelin: Phase 3 trial expected to reach primary completion November 11, 2026 (NCT05050084, active not recruiting). Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score, The Guidance Trial
- triptorelin: Phase 3 trial expected to reach primary completion November 11, 2026 (NCT05050084, active not recruiting). Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score, The Guidance Trial
- olatorepatide: Phase 2 trial expected to reach primary completion November 13, 2026 (NCT07431086, active not recruiting). Study of Olatorepatide in Adult Participants Living With Overweight or Obesity in the US
- ecnoglutide: Phase 2 trial expected to reach primary completion November 30, 2026 (NCT07553299, active not recruiting). A Study of Weekly Oral Dose of Ecnoglutide (VRB-101) for Weight Maintenance in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities
- efsubaglutide alfa: Phase 4 trial expected to reach primary completion November 30, 2026 (NCT07163650, recruiting). Evaluating Anti-Obesity Medications 6 Months After Metabolic Surgery
- cetrorelix: Phase 4 trial expected to reach primary completion December 2026 (NCT07350317, not yet recruiting). Trial Comparing Subcutaneous Natural Progesterone (Prolutex) vs. Cetrorelix Acetate for Luteinizing Hormone Surge Suppression in Freeze-All IVF Cycles.
- gozetotide: Phase 2 trial expected to reach primary completion December 30, 2026 (NCT06145633, recruiting). Vorinostat and 177Lu-PSMA-617 for the Treatment of PSMA-Low Metastatic Castration-Resistant Prostate Cancer
- teriparatide: Phase 4 trial expected to reach primary completion December 30, 2026 (NCT04589819, enrolling by invitation). Fracture Recovery for Returning to Duty (Teriparatide STRONG)
- vipivotide tetraxetan lutetium: Phase 2 trial expected to reach primary completion December 30, 2026 (NCT06145633, recruiting). Vorinostat and 177Lu-PSMA-617 for the Treatment of PSMA-Low Metastatic Castration-Resistant Prostate Cancer
Registered dates that have passed
These studies' estimated completion dates are behind us and the registry has not been updated, which is worth knowing in itself.
- afamelanotide: Phase 3 trial expected to reach primary completion December 2025 (NCT06109649, active not recruiting). A Study to Compare the Efficacy and Safety of SCENESSE and Narrow-Band Ultraviolet (NB-UVB) Light Versus NB-UVB Light Alone in Patients With Vitiligo
- certepetide: Phase 2 trial expected to reach primary completion September 2025 (NCT05121038, active not recruiting). CEND-1 in Combination with Neoadjuvant FOLFIRINOX with or Without Panitumumab
- lypressin: trial expected to reach primary completion June 30, 2024 (NCT05266534, recruiting). The Effect of Intramyometrial Injection of Terlipressin Versus Carbitocin on Hemoglobin and Blood Loss During Open Myomectomy Operations Without Using Haemostatic Tourniquets
- nesiritide: Phase 2 trial expected to reach primary completion December 2018 (NCT02608996, recruiting). Nesiritide in Hypertension
- terlipressin: Phase 2 trial expected to reach primary completion May 2026 (NCT06256432, active not recruiting). Endothelin Receptor Antagonism With Ambrisentan to Treat Hepatorenal Syndrome
All 331 molecules
331 of 331 shown
| Most advanced active study | Lead sponsors | First approval | ||||
|---|---|---|---|---|---|---|
| abaloparatide | Approved (phase 4) | Phase 4 | 6 | February 2027 NCT03841058 | Hospital for Special Surgery, New York, State University of New York at Buffalo | 2017 |
| abarelix | Approved (phase 4) | — | 0 | — | — | 2003 |
| aclerastide | Phase 3 | — | 0 | — | — | — |
| act-1 peptide | Phase 3 | — | 0 | — | — | — |
| afamelanotide | Approved (phase 4) | Phase 3 | 1 | December 2025 NCT06109649 | Clinuvel, Inc. | 2014 |
| albiglutide | Approved (phase 4) | — | 1 | May 31, 2026 NCT05220917 | Brigham and Women's Hospital | 2014 |
| albuvirtide | Phase 3 | — | 2 | July 2028 NCT07727642 | Shanghai Public Health Clinical Center, Shanxi Bethune Hospital | — |
| alizulatide vixocianine | Phase 2 | — | 0 | — | — | — |
| almurtide | Phase 2 | — | 0 | — | — | — |
| alsactide | Phase 2 | — | 0 | — | — | — |
| amilomotide | Phase 2 | — | 0 | — | — | — |
| amlintide | Phase 2 | — | 1 | October 2026 NCT07506369 | University Hospital, Gentofte, Copenhagen | — |
| anamorelin | Phase 3 | Phase 3 | 2 | December 31, 2026 NCT03637816 | M.D. Anderson Cancer Center | — |
| anaritide acetate | Phase 2 | — | 0 | — | — | — |
| anfibatide | Phase 2 | — | 0 | — | — | — |
| argipressin tannate | Phase 2 | — | 0 | — | — | — |
| argiprestocin | Phase 2 | — | 0 | — | — | — |
| aspartocin | Phase 2 | — | 0 | — | — | — |
| avexitide | Phase 3 | Phase 3 | 1 | July 8, 2026 NCT06747468 | Amylyx Pharmaceuticals Inc. | — |
| avorelin | Phase 2 | — | 0 | — | — | — |
| azetirelin | Phase 2 | — | 0 | — | — | — |
| balixafortide | Phase 3 | Phase 1 | 1 | February 2027 NCT06981806 | Arsen Osipov | — |
| baloramotide | Phase 2 | — | 0 | — | — | — |
| betiatide | Phase 2 | — | 0 | — | — | — |
| bevemipretide | Phase 2 | — | 0 | — | — | — |
| bibapcitide | Phase 2 | — | 0 | — | — | — |
| bofanglutide | Phase 2 | Phase 3 | 2 | October 2027 NCT07628985 | Carnot Laboratories | — |
| bremelanotide | Approved (phase 4) | Phase 2 | 1 | February 5, 2025 NCT06565611 | Palatin Technologies, Inc | 2019 |
| brimapitide | Phase 3 | — | 0 | — | — | — |
| bulevirtide | Approved (phase 4) | Phase 3 | 10 | November 2026 NCT07142811 | Vir Biotechnology, Inc., Mirum Pharmaceuticals, Inc. | 2020 |
| buserelin | Approved (phase 4) | Phase 3 | 3 | November 11, 2026 NCT05050084 | NRG Oncology, Proton Collaborative Group | — |
| cagrilintide | Phase 3 | Phase 3 | 16 | March 1, 2027 NCT07011667 | Novo Nordisk A/S | — |
| canvuparatide | Phase 2 | Phase 3 | 1 | January 2028 NCT07699471 | MBX Biosciences | — |
| capromab pendetide | Approved (phase 4) | — | 0 | — | — | 1996 |
| capromorelin | Phase 2 | — | 0 | — | — | — |
| carbetocin | Approved (phase 4) | Phase 4 | 14 | March 1, 2028 NCT07401524 | Sheba Medical Center, Mansoura University | — |
| cargutocin | Phase 2 | — | 0 | — | — | — |
| carperitide | Phase 3 | — | 0 | — | — | — |
| cenderitide | Phase 2 | — | 0 | — | — | — |
| certepetide | Phase 2 | Phase 2 | 2 | September 2025 NCT05121038 | Anup Kasi, Qilu Pharmaceutical Co., Ltd. | — |
| ceruletide | Approved (phase 4) | — | 0 | — | — | 1982 |
| ceruletide diethylamine | Approved (phase 4) | — | 0 | — | — | 1982 |
| cetrorelix | Approved (phase 4) | Phase 4 | 8 | December 2026 NCT07350317 | Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany, Trust Fertility Clinic | 1999 |
| cibinetide | Phase 2 | — | 0 | — | — | — |
| cilengitide | Phase 3 | — | 0 | — | — | — |
| codactide | Phase 2 | — | 0 | — | — | — |
| copper (64cu) adarulatide tetraxetan | Phase 2 | — | 0 | — | — | — |
| copper oxodotreotide | Approved (phase 4) | — | 0 | — | — | 2020 |
| copper oxodotreotide cu-64 | Approved (phase 4) | — | 0 | — | — | 2020 |
| corticorelin | Phase 3 | Phase 1 | 2 | July 24, 2022 NCT04037605 | Peter y. Liu, Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center | — |
| corticorelin ovine triflutate | Approved (phase 4) | — | 0 | — | — | 1996 |
| cotadutide | Phase 2 | — | 0 | — | — | — |
| dalazatide | Phase 2 | — | 0 | — | — | — |
| danegaptide | Phase 3 | — | 0 | — | — | — |
| dapiglutide | Phase 2 | Phase 2 | 1 | April 24, 2024 NCT05788601 | University Hospital, Gentofte, Copenhagen | — |
| davalintide | Phase 2 | — | 0 | — | — | — |
| davunetide | Phase 2 | — | 0 | — | — | — |
| dazdotuftide | Phase 3 | — | 0 | — | — | — |
| degarelix | Approved (phase 4) | Phase 4 | 40 | November 2026 NCT03951831 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, University of Colorado, Denver | 2008 |
| delmitide | Phase 2 | — | 0 | — | — | — |
| demoxytocin | Phase 2 | — | 0 | — | — | — |
| depreotide | Approved (phase 4) | — | 0 | — | — | 1999 |
| deslorelin | Phase 2 | — | 0 | — | — | — |
| desmopressin | Approved (phase 4) | Phase 4 | 14 | February 2027 NCT06337838 | Hospital de Clinicas de Porto Alegre, Medical University of Bialystok | 1978 |
| detirelix acetate | Phase 2 | — | 0 | — | — | — |
| diamfenetide | Phase 2 | — | 0 | — | — | — |
| diclometide | Phase 2 | — | 0 | — | — | — |
| dirucotide | Phase 3 | — | 0 | — | — | — |
| disaccharide tripeptide glycerol dipalmitoyl | Phase 2 | — | 0 | — | — | — |
| disitertide | Phase 2 | — | 0 | — | — | — |
| disomotide | Phase 2 | — | 0 | — | — | — |
| dolcanatide | Phase 2 | — | 0 | — | — | — |
| doreptide | Phase 2 | — | 0 | — | — | — |
| dulaglutide | Approved (phase 4) | Phase 4 | 15 | October 1, 2026 NCT06257966 | Eli Lilly and Company, National University of Singapore | 2014 |
| dumorelin | Phase 2 | — | 0 | — | — | — |
| dusquetide | Phase 3 | — | 0 | — | — | — |
| ebiratide | Phase 2 | — | 0 | — | — | — |
| ecallantide | Approved (phase 4) | — | 0 | — | — | 2009 |
| ecnoglutide | Phase 3 | Phase 3 | 7 | November 30, 2026 NCT07553299 | Hangzhou Sciwind Biosciences Co., Ltd., Verdiva Bio Dev Limited | — |
| ederimotide | Phase 2 | — | 0 | — | — | — |
| edotreotide | Phase 3 | Phase 3 | 4 | June 2027 NCT04919226 | ITM Solucin GmbH, Grupo Espanol de Tumores Neuroendocrinos | — |
| edotreotide gallium ga-68 | Approved (phase 4) | — | 0 | — | — | 2016 |
| edotreotide yttrium | Phase 2 | — | 0 | — | — | — |
| edotreotide yttrium y-90 | Phase 2 | — | 0 | — | — | — |
| edratide | Phase 2 | — | 0 | — | — | — |
| efinopegdutide | Phase 2 | — | 0 | — | — | — |
| efmedaglutide alfa | Phase 2 | — | 0 | — | — | — |
| efocipegtrutide | Phase 2 | — | 0 | — | — | — |
| efpeglenatide | Phase 3 | — | 0 | — | — | — |
| efsubaglutide alfa | Phase 2 | Phase 4 | 6 | November 30, 2026 NCT07163650 | Shanghai Yinnuo Pharmaceutical Technology Co., Ltd., The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | — |
| elamipretide | Phase 3 | Phase 4 | 3 | August 2027 NCT06373731 | Stealth BioTherapeutics Inc., David Marcinek | — |
| eloralintide | Phase 2 | Phase 3 | 15 | March 2027 NCT07215559 | Eli Lilly and Company | — |
| elpamotide | Phase 2 | — | 0 | — | — | — |
| elsiglutide | Phase 2 | — | 0 | — | — | — |
| emideltide | Phase 2 | — | 0 | — | — | — |
| enavermotide | Phase 2 | — | 0 | — | — | — |
| eneboparatide | Phase 2 | Phase 3 | 1 | November 15, 2024 NCT05778071 | Alexion Pharmaceuticals, Inc. | — |
| enfuvirtide | Approved (phase 4) | — | 0 | — | — | 2003 |
| enlicitide | Phase 3 | Phase 3 | 8 | October 12, 2027 NCT07614984 | Merck Sharp & Dohme LLC | — |
| enlicitide chloride | Phase 2 | — | 0 | — | — | — |
| enlicitide decanoate | Phase 3 | Phase 3 | 7 | October 12, 2027 NCT07614984 | Merck Sharp & Dohme LLC | — |
| ensereptide | Phase 2 | — | 0 | — | — | — |
| eptifibatide | Approved (phase 4) | Phase 3 | 1 | September 30, 2029 NCT07347626 | Xinqiao Hospital of Chongqing | 1998 |
| etarfolatide | Phase 2 | — | 0 | — | — | — |
| etelcalcetide | Approved (phase 4) | Phase 3 | 3 | June 30, 2027 NCT03969329 | Amgen | 2016 |
| etimumotide | Phase 2 | — | 0 | — | — | — |
| examorelin | Phase 2 | — | 0 | — | — | — |
| exenatide | Approved (phase 4) | Phase 4 | 8 | December 31, 2025 NCT05482789 | Seattle Children's Hospital, Maisa N. Feghali, MD | 2005 |
| felypressin | Phase 2 | — | 0 | — | — | — |
| fequesetide | Phase 2 | — | 0 | — | — | — |
| fertirelin | Phase 2 | — | 0 | — | — | — |
| fexapotide | Phase 3 | — | 0 | — | — | — |
| fexapotide triflutate | Phase 3 | — | 0 | — | — | — |
| fluciclatide | Phase 2 | — | 0 | — | — | — |
| fluciclatide f 18 | Phase 2 | — | 0 | — | — | — |
| froniglutide | Phase 2 | — | 0 | — | — | — |
| gallium (68ga) rofapitide tetraxetan | Phase 2 | — | 0 | — | — | — |
| gallium oxodotreotide | Approved (phase 4) | Phase 2 | 6 | November 2, 2026 NCT05691465 | OHSU Knight Cancer Institute, Mayo Clinic | 2016 |
| gallium rofapitidexetan | Phase 2 | — | 0 | — | — | — |
| ganipatide | Phase 2 | — | 0 | — | — | — |
| ganirelix | Approved (phase 4) | Phase 4 | 4 | October 31, 2026 NCT06745466 | University of Delaware | 1999 |
| gersizangitide | Phase 2 | — | 0 | — | — | — |
| ghrelin | Phase 3 | Phase 2 | 5 | December 16, 2007 NCT03338387 | Charles University, Czech Republic | — |
| giractide | Phase 2 | — | 0 | — | — | — |
| glepaglutide | Phase 3 | Phase 3 | 2 | September 18, 2028 NCT07228403 | Zealand Pharma | — |
| glisentide | Phase 2 | — | 0 | — | — | — |
| glucagon-like peptide ii | Phase 3 | — | 0 | — | — | — |
| gonadorelin | Approved (phase 4) | Phase 3 | 4 | December 2028 NCT04390646 | Nelly Pitteloud | 1982 |
| goralatide | Phase 2 | — | 0 | — | — | — |
| goserelin | Approved (phase 4) | Phase 4 | 69 | November 2026 NCT05607004 | City of Hope Medical Center, Fudan University | 1989 |
| gozetotide | Approved (phase 4) | Phase 3 | 12 | December 30, 2026 NCT06145633 | Jonsson Comprehensive Cancer Center, Fred Hutchinson Cancer Center | 2020 |
| gozetotide alf-18 | Phase 3 | — | 0 | — | — | — |
| hepalatide | Phase 2 | Phase 3 | 2 | June 2027 NCT07309380 | Shanghai HEP Pharmaceutical Co., Ltd. | — |
| histrelin | Approved (phase 4) | Phase 3 | 5 | November 11, 2026 NCT05050084 | NRG Oncology, VA Office of Research and Development | 1991 |
| human c-peptide | Phase 2 | — | 0 | — | — | — |
| icrocaptide | Phase 2 | — | 0 | — | — | — |
| ilatreotide | Phase 2 | — | 0 | — | — | — |
| imsamotide | Phase 2 | — | 0 | — | — | — |
| indium in 111 satumomab pendetide | Approved (phase 4) | — | 0 | — | — | 1991 |
| indium pentetreotide | Approved (phase 4) | — | 0 | — | — | 1994 |
| invopressin | Phase 2 | — | 0 | — | — | — |
| iodine i124 evuzamitide | Phase 2 | — | 0 | — | — | — |
| ipamorelin | Phase 2 | — | 0 | — | — | — |
| irucalantide | Phase 2 | — | 0 | — | — | — |
| iturelix | Phase 2 | — | 0 | — | — | — |
| lagatide | Phase 2 | — | 0 | — | — | — |
| lancovutide | Phase 2 | — | 0 | — | — | — |
| lanreotide | Approved (phase 4) | Phase 4 | 8 | November 2026 NCT05050942 | Grupo Espanol de Tumores Neuroendocrinos, Antonio Fojo | 2007 |
| larazotide | Phase 3 | — | 0 | — | — | — |
| lead (212pb) bamzireotide navoxetan | Phase 2 | — | 0 | — | — | — |
| lead (212pb) lapemelanotide zapixetan | Phase 2 | — | 0 | — | — | — |
| lead bamzireotide navoxetan | Phase 2 | — | 0 | — | — | — |
| lead lapemelanotide zapixetan | Phase 2 | — | 0 | — | — | — |
| leconotide | Phase 2 | — | 0 | — | — | — |
| lenomorelin | Phase 2 | — | 0 | — | — | — |
| linaclotide | Approved (phase 4) | Phase 4 | 7 | October 2026 NCT03119584 | University of Florida, Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | 2012 |
| liraglutide | Approved (phase 4) | Phase 4 | 30 | December 31, 2026 NCT03856632 | University of Virginia, 4Moving Biotech | 2009 |
| livoletide | Phase 2 | — | 0 | — | — | — |
| lixisenatide | Approved (phase 4) | Phase 4 | 5 | June 30, 2027 NCT07173712 | Yanbing Li, Sanofi | 2013 |
| lorutengitide | Phase 2 | — | 0 | — | — | — |
| lsalt peptide | Phase 3 | Phase 2 | 1 | March 2027 NCT05879432 | Arch Biopartners Inc. | — |
| lucicebtide | Phase 2 | — | 0 | — | — | — |
| lusupultide | Phase 2 | — | 0 | — | — | — |
| lutetium (177lu) tezuvotide tetraxetan | Phase 2 | — | 0 | — | — | — |
| lutetium (lu177) rofapitide tetraxetan | Phase 2 | — | 0 | — | — | — |
| lutetium lu 177 zadavotide guraxetan | Phase 2 | Phase 3 | 1 | June 4, 2029 NCT07611110 | AstraZeneca | — |
| lutetium oxodotreotide | Approved (phase 4) | Phase 2 | 10 | November 2, 2026 NCT05691465 | National Cancer Institute (NCI), OHSU Knight Cancer Institute | 2017 |
| lutetium oxodotreotide lu-177 | Approved (phase 4) | Phase 2 | 10 | November 2, 2026 NCT05691465 | National Cancer Institute (NCI), OHSU Knight Cancer Institute | 2017 |
| lutetium rofapitidexetan | Phase 2 | — | 0 | — | — | — |
| lutetium tezuvotidexetan | Phase 2 | — | 0 | — | — | — |
| lutrelin | Phase 2 | — | 0 | — | — | — |
| lypressin | Approved (phase 4) | — | 1 | June 30, 2024 NCT05266534 | Wael Elbanna Clinic | 1982 |
| macimorelin | Approved (phase 4) | — | 0 | — | — | 2017 |
| maraciclatide | Phase 2 | — | 0 | — | — | — |
| maridebart cafraglutide | Phase 2 | Phase 3 | 15 | January 21, 2027 NCT06858878 | Amgen | — |
| marlumotide | Phase 2 | — | 0 | — | — | — |
| mazdutide | Phase 3 | Phase 4 | 16 | April 2027 NCT07843862 | West China Hospital, Tongji Hospital | — |
| mertiatide | Approved (phase 4) | — | 0 | — | — | 1990 |
| mibenratide | Phase 2 | — | 0 | — | — | — |
| mifamurtide | Approved (phase 4) | Phase 2 | 2 | July 31, 2033 NCT07787429 | UNICANCER, Anna Raciborska | 2009 |
| mifamurtide acid | Approved (phase 4) | — | 0 | — | — | 2009 |
| mifomelatide | Phase 2 | Phase 2 | 1 | October 2027 NCT06937177 | Endevica Bio | — |
| milpocitide | Phase 2 | — | 0 | — | — | — |
| modimelanotide | Phase 2 | — | 0 | — | — | — |
| montirelin | Phase 2 | — | 0 | — | — | — |
| motixafortide | Approved (phase 4) | Phase 4 | 6 | December 31, 2026 NCT07101445 | Guangzhou Gloria Biosciences Co., Ltd., Emory University | 2023 |
| murabutide | Phase 2 | — | 0 | — | — | — |
| nacartocin | Phase 2 | — | 0 | — | — | — |
| nafarelin | Approved (phase 4) | Phase 4 | 3 | September 2027 NCT06150703 | Fundacion Dexeus, Assistance Publique - Hôpitaux de Paris | 1990 |
| nangibotide | Phase 2 | Phase 2 | 1 | May 9, 2022 NCT04055909 | Inotrem | — |
| navepegritide | Phase 2 | Phase 2 | 3 | August 2027 NCT06732895 | Ascendis Pharma A/S, Ascendis Pharma Growth Disorders A/S | — |
| nemifitide | Phase 2 | — | 0 | — | — | — |
| nerinetide | Phase 3 | — | 0 | — | — | — |
| nesiritide | Approved (phase 4) | Phase 2 | 1 | December 2018 NCT02608996 | Oslo University Hospital | 2001 |
| nisotirostide | Phase 2 | — | 0 | — | — | — |
| noraramtide | Phase 2 | — | 0 | — | — | — |
| norleusactide | Phase 2 | — | 0 | — | — | — |
| nosiheptide | Phase 2 | — | 0 | — | — | — |
| obinepitide | Phase 2 | — | 0 | — | — | — |
| ociltide | Phase 2 | — | 0 | — | — | — |
| octreotide | Approved (phase 4) | Phase 4 | 34 | November 2026 NCT05050942 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd., Camurus AB | 1988 |
| olatorepatide | Phase 2 | Phase 2 | 3 | November 13, 2026 NCT07431086 | Regeneron Pharmaceuticals | — |
| omramotide | Phase 2 | — | 0 | — | — | — |
| onvitrelin ucalontide | Phase 2 | — | 0 | — | — | — |
| ornipressin | Phase 2 | — | 0 | — | — | — |
| orotirelin | Phase 2 | — | 0 | — | — | — |
| ovemotide | Phase 2 | — | 0 | — | — | — |
| oximbomotide | Phase 2 | — | 0 | — | — | — |
| oxytocin | Approved (phase 4) | Phase 4 | 81 | October 2026 NCT06036004 | University Hospital, Basel, Switzerland, Wake Forest University Health Sciences | 1980 |
| ozarelix | Phase 3 | — | 0 | — | — | — |
| palopegteriparatide | Approved (phase 4) | Phase 3 | 4 | June 2027 NCT07081997 | Ascendis Pharma Bone Diseases A/S, Ascendis Pharma A/S | 2023 |
| paluratide | Phase 2 | — | 0 | — | — | — |
| pancreatic polypeptide | Phase 2 | — | 1 | October 2026 NCT07506369 | University Hospital, Gentofte, Copenhagen | — |
| pareptide | Phase 2 | — | 0 | — | — | — |
| pasireotide | Approved (phase 4) | Phase 4 | 5 | October 29, 2026 NCT05928390 | University Hospital Heidelberg, Helsinki University Central Hospital | 2012 |
| pasireotide diaspartate | Approved (phase 4) | Phase 2 | 1 | October 29, 2026 NCT05928390 | RECORDATI GROUP | 2012 |
| peforelin | Phase 2 | — | 0 | — | — | — |
| pegapamodutide | Phase 2 | — | 0 | — | — | — |
| peginesatide | Approved (phase 4) | — | 0 | — | — | 2012 |
| pegloprastide | Phase 2 | — | 0 | — | — | — |
| pegmispotide | Phase 2 | — | 0 | — | — | — |
| pegsebrenatide | Phase 2 | — | 0 | — | — | — |
| pemvidutide | Phase 2 | Phase 3 | 2 | September 30, 2027 NCT07009860 | Altimmune, Inc. | — |
| pendetide | Phase 2 | — | 0 | — | — | — |
| pentetreotide | Approved (phase 4) | — | 0 | — | — | 1994 |
| pentigetide | Phase 2 | — | 0 | — | — | — |
| peptide t | Phase 2 | Phase 1 | 1 | November 2030 NCT07481136 | Javid Moslehi, MD | — |
| peptide yy human (3-36) | Phase 2 | — | 0 | — | — | — |
| petrelintide | Phase 2 | Phase 3 | 5 | November 12, 2027 NCT07589686 | Hoffmann-La Roche | — |
| pezadeftide | Phase 2 | — | 0 | — | — | — |
| pimelautide | Phase 2 | — | 0 | — | — | — |
| plecanatide | Approved (phase 4) | Phase 2 | 1 | October 18, 2027 NCT07723924 | Bausch Health Americas, Inc. | 2017 |
| pobrolitide | Phase 2 | — | 0 | — | — | — |
| posatirelin | Phase 2 | — | 0 | — | — | — |
| pr1 leukemia peptide vaccine | Phase 3 | — | 0 | — | — | — |
| pralmorelin | Phase 2 | — | 0 | — | — | — |
| pramlintide | Approved (phase 4) | Early phase 1 | 3 | October 2026 NCT07506369 | Boston University, University Hospital, Gentofte, Copenhagen | 2005 |
| prazarelix | Phase 2 | — | 0 | — | — | — |
| protirelin | Approved (phase 4) | — | 0 | — | — | 1976 |
| quazomotide | Phase 2 | — | 0 | — | — | — |
| ramorelix | Phase 2 | — | 0 | — | — | — |
| recanaclotide | Phase 2 | — | 0 | — | — | — |
| redasemtide | Phase 2 | — | 0 | — | — | — |
| relamorelin | Phase 3 | — | 0 | — | — | — |
| retatrutide | Phase 3 | Phase 3 | 11 | October 2026 NCT06297603 | Eli Lilly and Company, Hudson Biotech | — |
| rimtoregtide | Phase 2 | — | 0 | — | — | — |
| rismorelin | Phase 2 | — | 0 | — | — | — |
| rolipoltide | Phase 2 | — | 0 | — | — | — |
| romurtide | Phase 2 | — | 0 | — | — | — |
| rotigaptide | Phase 2 | — | 0 | — | — | — |
| rovatirelin | Phase 3 | — | 0 | — | — | — |
| rusalatide | Phase 2 | — | 0 | — | — | — |
| rusfertide | Phase 3 | Phase 3 | 4 | October 28, 2027 NCT07648030 | Takeda, Protagonist Therapeutics, Inc. | — |
| ruxotemitide | Phase 2 | — | 0 | — | — | — |
| satoreotide tetraxetan | Phase 2 | — | 0 | — | — | — |
| satoreotide trizoxetan | Phase 2 | — | 0 | — | — | — |
| seglitide | Phase 2 | — | 0 | — | — | — |
| selcopintide | Phase 2 | — | 0 | — | — | — |
| selepressin | Phase 2 | — | 0 | — | — | — |
| semaglutide | Approved (phase 4) | Phase 4 | 280 | October 15, 2026 NCT07505303 | Novo Nordisk A/S, Mayo Clinic | 2017 |
| semparatide | Phase 2 | — | 0 | — | — | — |
| seractide acetate | Approved (phase 4) | — | 0 | — | — | 1978 |
| sermorelin acetate | Approved (phase 4) | — | 0 | — | — | 1990 |
| setmelanotide | Approved (phase 4) | Phase 4 | 5 | October 31, 2026 NCT06772597 | Rhythm Pharmaceuticals, Inc., Massachusetts General Hospital | 2020 |
| sinapultide | Phase 2 | — | 0 | — | — | — |
| solnatide | Phase 2 | — | 0 | — | — | — |
| somatorelin | Approved (phase 4) | — | 0 | — | — | — |
| sonefpeglutide | Phase 2 | Phase 2 | 1 | December 2027 NCT04775706 | Hanmi Pharmaceutical Company Limited | — |
| sovatelitide | Phase 3 | — | 0 | — | — | — |
| sucantomotide | Phase 2 | — | 0 | — | — | — |
| sudocetaxel zendusortide | Phase 2 | — | 0 | — | — | — |
| sulglicotide | Phase 2 | — | 0 | — | — | — |
| survodutide | Phase 3 | Phase 3 | 10 | November 30, 2027 NCT07206290 | Boehringer Ingelheim, University Medical Center Groningen | — |
| svn53-67/m57-klh peptide vaccine | Phase 2 | Phase 2 | 3 | March 30, 2029 NCT07169617 | Roswell Park Cancer Institute, National Cancer Institute (NCI) | — |
| tabilautide | Phase 2 | — | 0 | — | — | — |
| tabimorelin | Phase 2 | — | 0 | — | — | — |
| talfirastide | Phase 2 | — | 0 | — | — | — |
| talogreptide mesaroxetan | Phase 2 | — | 0 | — | — | — |
| taltirelin | Phase 2 | — | 0 | — | — | — |
| taspoglutide | Phase 3 | — | 0 | — | — | — |
| tecemotide | Phase 3 | — | 0 | — | — | — |
| technetium (99mtc) apcitide | Approved (phase 4) | — | 0 | — | — | 1998 |
| technetium mertiatide | Approved (phase 4) | — | 0 | — | — | 1990 |
| teduglutide | Approved (phase 4) | Phase 3 | 4 | February 10, 2027 NCT06973304 | International Centre for Diarrhoeal Disease Research, Bangladesh, Takeda | 2012 |
| temurtide | Phase 2 | — | 0 | — | — | — |
| teprotide | Phase 2 | — | 0 | — | — | — |
| teriparatide | Approved (phase 4) | Phase 4 | 14 | December 30, 2026 NCT04589819 | Ditte Hansen, Massachusetts General Hospital | 1987 |
| terlipressin | Approved (phase 4) | Phase 3 | 9 | May 2026 NCT06256432 | Noorik Biopharmaceuticals AG, Institute of Liver and Biliary Sciences, India | 2022 |
| tertomotide | Phase 3 | Phase 3 | 1 | January 2028 NCT05303701 | Samsung Pharmaceutical Co., Ltd. | — |
| tesamorelin | Approved (phase 4) | Phase 2 | 3 | February 14, 2027 NCT07481734 | Massachusetts General Hospital, Johns Hopkins University | 2010 |
| teverelix | Phase 2 | Phase 2 | 2 | September 2027 NCT07457164 | Antev Ltd. | — |
| tifuvirtide | Phase 2 | — | 0 | — | — | — |
| tigapotide | Phase 2 | — | 0 | — | — | — |
| tiplimotide | Phase 2 | — | 0 | — | — | — |
| tirzepatide | Approved (phase 4) | Phase 4 | 162 | October 30, 2026 NCT06861439 | Eli Lilly and Company, Mayo Clinic | 2022 |
| tosactide | Phase 2 | — | 0 | — | — | — |
| tozuleristide | Phase 2 | — | 0 | — | — | — |
| tricosactide | Phase 2 | — | 0 | — | — | — |
| tridecactide | Phase 3 | — | 0 | — | — | — |
| triletide | Phase 2 | — | 0 | — | — | — |
| triptorelin | Approved (phase 4) | Phase 4 | 36 | November 11, 2026 NCT05050084 | H. Lee Moffitt Cancer Center and Research Institute, NRG Oncology | 2000 |
| trofinetide | Approved (phase 4) | — | 1 | June 2027 NCT06705816 | University of Minnesota | 2023 |
| trolamine polypeptide oleate condensate | Approved (phase 4) | — | 0 | — | — | 1958 |
| ucasareotide dasaroxetan | Phase 2 | — | 0 | — | — | — |
| ularitide | Phase 3 | — | 0 | — | — | — |
| ulimorelin | Phase 3 | — | 0 | — | — | — |
| utreglutide | Phase 2 | — | 0 | — | — | — |
| vanutide cridificar | Phase 2 | — | 0 | — | — | — |
| vapreotide | Phase 3 | — | 0 | — | — | — |
| vasoactive intestinal peptide | Phase 3 | — | 0 | — | — | — |
| vasopressin | Approved (phase 4) | Phase 4 | 29 | October 1, 2026 NCT02118467 | Hospital do Coracao, Assistance Publique - Hôpitaux de Paris | 2014 |
| vasopressin tannate | Approved (phase 4) | — | 0 | — | — | 1982 |
| veldoreotide | Phase 2 | — | 0 | — | — | — |
| vensemaglutide | Phase 2 | — | 0 | — | — | — |
| vezocolmitide | Phase 2 | — | 0 | — | — | — |
| vicatertide | Phase 2 | — | 0 | — | — | — |
| vipivotide tetraxetan | Approved (phase 4) | Phase 4 | 38 | October 15, 2026 NCT06894511 | Novartis Pharmaceuticals, University of Washington | 2022 |
| vipivotide tetraxetan gallium | Phase 2 | Phase 2 | 1 | September 1, 2028 NCT06039371 | University of Washington | — |
| vipivotide tetraxetan gallium ga-68 | Phase 2 | Phase 2 | 1 | September 1, 2028 NCT06039371 | University of Washington | — |
| vipivotide tetraxetan lutetium | Approved (phase 4) | Phase 2 | 8 | December 30, 2026 NCT06145633 | Jonsson Comprehensive Cancer Center, University of Washington | 2022 |
| visepegenatide | Phase 2 | — | 0 | — | — | — |
| vorumotide | Phase 2 | — | 0 | — | — | — |
| vosoritide | Approved (phase 4) | Phase 3 | 13 | March 2027 NCT06668805 | BioMarin Pharmaceutical, Andrew Dauber | 2021 |
| vurolenatide | Phase 2 | — | 0 | — | — | — |
| xelafaslatide | Phase 2 | — | 0 | — | — | — |
| zelenectide | Phase 2 | Phase 2 | 4 | March 2028 NCT06225596 | BicycleTx Limited | — |
| zelenectide pevedotin | Phase 2 | Phase 2 | 4 | March 2028 NCT06225596 | BicycleTx Limited | — |
| zendusortide | Phase 2 | — | 0 | — | — | — |
| ziconotide | Approved (phase 4) | — | 3 | September 2027 NCT04321408 | Christian Hospital Northeast Northwest, ESTEVE Pharmaceuticals SAS | 2004 |
| zifogaptide | Phase 2 | — | 0 | — | — | — |
| zoptarelin doxorubicin | Phase 3 | — | 0 | — | — | — |
Phase is ChEMBL's highest recorded phase for the molecule; the active-study columns come from ClinicalTrials.gov studies that are recruiting, not yet recruiting, active or enrolling by invitation. Method and field definitions: _ops/pipeline_data.py in the published dataset notes, and methodology.